Saccharomyces cerevisiae fungemia: An emerging infectious disease

Clinical Infectious Diseases

Volumn 40, Issue 11, 2005, Pages 1625-1634

  Muñoz, Patricia ^a   Bouza, Emilio ^a   Cuenca Estrella, Manuel ^b   Eiros, José María ^a   Pérez, Maria Jesús ^a   Sánchez Somolinos, Mar ^a   Rincón, Cristina ^a   Hortal, Javier ^a   Peláez, Teresa ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; PROBIOTIC AGENT; ULTRALEVURA; VORICONAZOLE;

BACTERIUM CULTURE; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE; DIARRHEA; DNA FINGERPRINTING; EPIDEMIC; FUNGEMIA; FUNGUS ISOLATION; GENE AMPLIFICATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NASOGASTRIC TUBE; PARENTERAL NUTRITION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE;

AGED; ANTIFUNGAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; FEMALE; FUNGEMIA; HUMANS; PROBIOTICS; SACCHAROMYCES CEREVISIAE;

EID: 19344376750     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429916     Document Type: Review

References (85)

1. McCullough MJ, Clemons KV, McCusker JH, Stevens DA. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998; 36:2613-7.
2. Eddy JT, Stamatakis MK, Makela EH. Saccharomyces boulardii for the treatment of Clostridium difficile-associated colitis. Ann Pharmacother 1997; 31:919-21.
3. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003; 41:5340-3.
4. Bleichner G, Blèhaut H, Mente H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med 1997; 23:517-23.
5. de Hoog GS, Guarro J, Gene J, Figueres MJ. Atlas of clinical fungi. Utrecht, The Netherlands and Reus, Spain: Centraalbureau voor Schimmelcultures/Universitat Rovira i Virgili, 2000.
6. Kurtzman CP, Fell JW. The yeasts: a taxonomic study. Amsterdam: Elsevier, 1998.
7. Rodriguez-Tudela JL, Barchiesi F, Bille J, et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect 2003; 9:1-8.
8. Diaz-Guerra TM, Martinez-Suarez JV, Laguna F, Valencia E, Rodriguez-Tudela JL. Change in fluconazole susceptibility patterns and genetic relationship among oral Candida albicans isolates. AIDS 1998; 12:1601-10.
9. Gadea I, Cuenca-Estrella M, Prieto E, et al. Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital. J Clin Microbiol 2004; 42:1832-6.
10. Stein PD, Folkens AT, Hruska KA. Saccharomyces fungemia. Chest 1970; 58:173-5.
11. Rubinstein E, Noriega ER, Simberkoff MS, Holzman R, Rahal JJ. Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore) 1975; 54:331-45.
12. Noriega ER, Rubinstein E, Simberkoff MS, Rahal JJ. Subacute and acute endocarditis due to Pseudomonas cepacia in heroin addicts. Am J Med 1975; 59:29-36.
13. Jensen DP, Smith DL. Fever of unknown origin secondary to Brewer's yeast ingestion. Arch Intern Med 1976; 136:332-3.
14. Eschete ML, West BC. Saccharomyces cerevisiae septicemia. Arch Intern Med 1980; 140:1539.
15. Cimolai N, Gill MJ, Church D. Saccharomyces cerevisiae fungemia: case report and review of the literature. Diagn Microbiol Infect Dis 1987; 8:113-7.
16. Sethi N, Mandell W. Saccharomyces fungemia in a patient with AIDS. N Y State J Med 1988; 88:278-9.
17. Anaissie E, Bodey GP, Kantarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989; 11:369-78.
18. Manzella JP, Shaffer S, Agarwal N, Kellogg JA. Saccharomyces cerevisiae fungemia in a multiply traumatized patient. J Trauma 1989; 29:129-30.
19. Aucott JN, Fayen J, Grossnicklas H, Morrissey A, Lederman MM, Salata RA. Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev Infect Dis 1990; 12:406-11.
20. Nielsen H, Stenderup J, Bruun B. Fungemia with Saccharomycetaceae: report of four cases and review of the literature. Scand J Infect Dis 1990; 22:581-4.
21. Zunic P, Lacotte J, Pegoix M, et al. Saccharomyces boulardii fungemia: apropos of a case [in French]. Therapie 1991; 46:498-9.
22. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72:78-89.
23. Oriol A, Ribera JM, Arnal J, Milla F, Batlle M, Feliu E. Saccharomyces cerevisiae septicemia in a patient with myelodysplastic syndrome. Am J Hematol 1993; 43:325-6.
24. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995; 21:113-5.
25. Viggiano M, Badetti C, Bernini V, Garabedian M, Manelli JC. Saccharomyces boulardii fungemia in a patient with severe burns [in French]. Ann Fr Anesth Reanim 1995; 14:356-8.
26. Muehrcke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995; 60:538-43.
27. Cairoli R, Marenco P, Perego R, de Cataldo F. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transplant 1995; 15:785-6.
28. Fung KS, Scheel O, Lyon DJ, Cheng AF, Bendeck J. Self-inflicted bacteraemia and fungaemia in Vietnamese migrants. Scand J Infect Dis 1996; 28:83-5.
29. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1→3)-β-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35:371-4.
30. Fredenucci I, Chomarat M, Boucaud C, Flandrois JP. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 1998; 27:222-3.
31. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105:71-2.
32. Fiore NF, Conway JH, West KW, Kleiman MB. Saccharomyces cerevisiae infections in children. Pediatr Infect Dis J 1998; 17:1177-9.
33. Pavese P, Brion JP, Lebeau B, Grillot R, Ambroise-Thomas P. Epidemiology of fungemia in a university hospital; therapeutic incidence [in French]. Pathol Biol (Paris) 1999; 47:579-83.
34. Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999; 28:930.
35. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000; 8:504-5.
36. Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000; 19:468-70.
37. Rijnders BJ, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26:825.
38. Ubeda P, Viudes A, Perez Belles C, Marques JL, Peman J, Gobernado M. Endocarditis por Saccharomyces cerevisiae sobre válvula protesica. Enferm Infecc Microbiol Clin 2000; 18:142.
39. Ubeda P, Perez C, Blanes M, Viudes A, Peman J, Gobernado M. Endocarditis infecciosa por levaduras. Enferm Infecc Microbiol Clin 2001; 19:500-2.
40. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19:16-20.
41. Heath CH, Jaksic A, McKerracher D, Clarke GM. Disseminated Saccharomyces cerevisiae infection following polymicrobial hepatobiliary sepsis. Aust N Z J Med 2000; 30:521-2.
42. Ipson MA, Blanco CL. Saccharomyces cerevisiae sepsis in a 35-week-old premature infant: a case report. J Perinatol 2001; 21:459-60.
43. Ruiz-Esquide F, Diaz MC, Wu E, Silva V. Verrucous endocarditis secondary to Saccharomyces cerevisiae: a case report [in Spanish]. Rev Med Chil 2002; 130:1165-9.
44. Smith D, Metzgar D, Wills C, Fierer J. Fatal Saccharomyces cerevisiae aortic graft infection. J Clin Microbiol 2002; 40:2691-2.
45. Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28:797-801.
46. Riquelme AJ, Calvo MA, Guzman AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36:41-3.
47. Lungarotti MS, Mezzetti D, Radicioni M. Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida. Arch Dis Child Fetal Neonatal Ed 2003; 88:F446.
48. Piarroux R, Millon L, Bardonnet K, Vagner O, Koenig H. Are live Saccharomyces yeasts harmful to patients? Lancet 1999; 353:1851-2.
49. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27:1138-47.
50. Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Trends and sources of nosocomial fungaemia. Mycoses 1994; 37:187-90.
51. Debelian GJ, Olsen I, Tronstad L. Observation of Saccharomyces cerevisiae in blood of patient undergoing root canal treatment. Int Endod J 1997; 30:313-7.
52. Olver WJ, James SA, Lennard A, et al. Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect 2002; 52:268-72.
53. Dougherty SH, Simmons RL. Postoperative peritonitis caused by Saccharomyces cerevisiae. Arch Surg 1982; 117:248.
54. Doyle MG, Pickering LK, O'Brien N, Hoots K, Benson JE. Saccharomyces cerevisiae infection in a patient with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1990; 9:850-1.
55. Eng RH, Drehmel R, Smith SM, Goldstein EJ. Saccharomyces cerevisiae infections in man. Sabouraudia 1984; 22:403-7.
56. Chertow GM, Marcantonio ER, Wells RG. Saccharomyces cerevisiae empyema in a patient with esophago-pleural fistula complicating variceal sclerotherapy. Chest 1991; 99:1518-9.
57. Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001; 39:551-9.
58. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996; 22:200-1.
59. Salonen JH, Richardson MD, Gallacher K, et al. Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae. J Hosp Infect 2000; 45:293-301.
60. Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996; 34:3031-4.
61. Clemons KV, McCusker JH, Davis RW, Stevens DA. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J Infect Dis 1994; 169:859-67.
62. Clemons KV, Hanson LC, Stevens DA. Colony phenotype switching in clinical and non-clinical isolates of Saccharomyces cerevisiae. J Med Vet Mycol 1996; 34:259-64.
63. Mydlik M, Tkacova E, Szovenyiova K, Mizla P, Derzsiova K. Saccharomyces cerevisiae peritonitis complicating CAPD. Perit Dial Int 1996; 16:188.
64. Snyder S. Peritonitis due to Saccharomyces cerevisiae in a patient on CAPD. Perit Dial Int 1992; 12:77-8.
65. Posteraro B, Sanguinetti M, D'Amore G, Masucci L, Morace G, Fadda G. Molecular and epidemiological characterization of vaginal Saccharomyces cerevisiae isolates. J Clin Microbiol 1999; 37:2230-5.
66. McCullough MJ, Clemons KV, Farina C, McCusker JH, Stevens DA. Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypic method. J Clin Microbiol 1998; 36:557-62.
67. Garcia-Martos P, Hernandez JM, Mira J, Galan F, Marin P. Saccharomyces cerevisiae vaginitis [in Spanish]. Enferm Infecc Microbiol Clin 1996; 14:453-4.
68. Nyirjesy P, Vazquez JA, Ufberg DD, Sobel JD, Boikov DA, Buckley HR. Saccharomyces cerevisiae vaginitis: transmission from yeast used in baking. Obstet Gynecol 1995; 86:326-9.
69. Konecny P, Drummond FM, Tish KN, Tapsall JW. Saccharomyces cerevisiae oesophagitis in an HIV-infected patient. Int J STD AIDS 1999; 10:821-2.
70. van Doorn HC, Coelingh Bennink F. Vaginal infection caused by Saccharomyces cerevisiae [in Dutch]. Ned Tijdschr Geneeskd 1995; 139:1093-5.
71. Senneville E, Ajana F, Gerard Y, et al. Bilateral ureteral obstruction due to Saccharomyces cerevisiae fungus balls. Clin Infect Dis 1996; 23:636-7.
72. Almanza L, Debien B, Fontaine B, Brinquin L. Four hours for a record, or a severe fuminating cellulitis: can Saccharomyces cerevisiae be the causal agent [in French]? Ann Fr Anesth Reanim 1998; 17:130-2.
73. Bernstein CN, Orr K, Blanchard JF, Sargent M, Workman D. Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn's disease. Can J Gastroenterol 2001; 15:499-504.
74. Darroch CJ, Barnes RM, Dawson J. Circulating antibodies to Saccharomyces cerevisiae (bakers'/brewers' yeast) in gastrointestinal disease. J Clin Pathol 1999; 52:47-53.
75. Candelli M, Papa A, Nista EC, et al. Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? Hepatogastroenterology 2003; 50:718-20.
76. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988; 297:1105-6.
77. Belchi-Hernandez J, Mora-Gonzalez A, Iniesta-Perez J. Baker's asthma caused by Saccharomyces cerevisiae in dry powder form. J Allergy Clin Immunol 1996; 97:131-4.
78. Candelli M, Nista EC, Nestola M, et al. Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol 2003; 36:39-40.
79. Kontoyiannis DP. Fluconazole inhibits pseudohyphal growth in Saccharomyces cerevisiae. Chemotherapy 2000; 46:100-3.
80. Sobel JD, Vazquez J, Lynch M, Meriwether C, Zervos MJ. Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. Clin Infect Dis 1993; 16:93-9.
81. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44:226-9.
82. Canton E, Peman J, Orero A, et al. In vitro activity of posaconazole against yeasts isolated in blood cultures [in Spanish]. Rev Esp Quimioter 2002; 15:335-40.
83. Swinne D, Watelle M, Van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses 2004; 47:177-83.
84. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36:198-202.
85. Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233-5.